Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016-Reference-Cited by-同舟云学术

Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016

Published:2022-05-24 Issue:5 Volume:5 Page:e2213588
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Shen Chan¹²,Tannenbaum Daniel³,Horn Robert³,Rogers Jane⁴,Eng Cathy⁵,Zhou Shouhao⁶,Johnson Benny⁷,Kopetz Scott⁷,Morris Van⁷,Overman Michael⁷,Parseghian Christine⁷,Chang George J.⁸⁹,Lopez-Olivo Maria A.⁹,Kanwal Raghav⁷,Ellis Lee M.⁸,Dasari Arvind⁷

Affiliation:

1. Division of Health Outcomes Research and Quality, Department of Surgery, Penn State College of Medicine, Hershey, Pennsylvania

2. Division of Health Services and Behavioral Research, Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania

3. Department of Internal Medicine, The University of Texas Health Sciences Center at Houston, Houston

4. Department of Pharmacy Clinical Programs, the University of Texas MD Anderson Cancer Center, Houston

5. Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

6. Division of Biostatistics and Bioinformatics, Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania

7. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston

8. Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston

9. Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2792599/shen_2022_oi_220402_1652711409.95122.pdf

Reference35 articles.

1. Colorectal cancer.;Dekker;Lancet,2019

2. Improved outcomes in metastatic colon cancer: giving credit where credit is due.;Sargent;JAMA Oncol,2015

3. How much do clinical trials cost?;Martin;Nat Rev Drug Discov,2017

4. Trends in clinical success rates and therapeutic focus.;Dowden;Nat Rev Drug Discov,2019

5. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.;Page;BMJ,2021

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Public Preference for Off-Label Use of Drugs for Cancer Treatment and Relative Importance of Associated Adverse Events: A Discrete Choice Experiment and Best-Worst Scaling;Applied Health Economics and Health Policy;2024-09-10

2. Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group;Japanese Journal of Clinical Oncology;2024-08-29

3. Serum Uric Acid Level May Be a Predictive Factor for BRAF V600E Mutation in Older Patients with Metastatic Colorectal Cancer: An Exploratory Analysis;Oncology;2024-07-17

4. Colorectal cancer;The Lancet;2024-07

5. Cost-effectiveness analysis of fruquintinib in Chinese patients with refractory metastatic colorectal cancer;International Journal of Clinical Pharmacy;2024-04-20